Oncolytics Biotech® Inc. Announces Closing of Common Share Offering
CALGARY, Feb. 25, 2013
CALGARY, Feb. 25, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics")
(TSX:ONC; NASDAQ:ONCY) announced today that it has closed its previously
announced underwritten public offering of 8.0 million common shares, at a
public offering price of US$4.00 per common share. The aggregate gross
proceeds from the offering, before deducting underwriting discounts and
commissions and offering expenses payable by Oncolytics, were approximately
The offering was conducted by Piper Jaffray & Co. and Wedbush PacGrow Life
Sciences acting as joint book-running managers for the offering in the U.S.
and Paradigm Capital Inc. acting as co-manager in the U.S. and book-running
manager in Canada.
The Company has granted to the underwriters participating in the offering a
30-day option to purchase up to an additional 1.2 million common shares to
cover over-allotments, if any.
Oncolytics intends to use the net proceeds from the offering to fund its
clinical trial program, manufacturing program and for general corporate and
working capital purposes.
The common shares were offered in each of the Canadian provinces of British
Columbia, Alberta, Manitoba and Ontario by way of a prospectus supplement to
the Company's base shelf short form prospectus and in the United States
pursuant to a prospectus supplement to the Company's effective shelf
registration statement on Form F-10 (333-182260) previously filed with the
United States Securities and Exchange Commission. Copies of the prospectus
supplement and accompanying base prospectus relating to the offering may be
obtained from the Securities and Exchange Commission website at
http://www.sec.gov, from the System for Electronic Document Analysis and
Retrieval (SEDAR) website at http://www.sedar.com or from the underwriters at:
Piper Jaffray & Co.
800 Nicollet Mall, J12S03, Minneapolis, MN 55402
Telephone: (800) 747-3924
Wedbush Securities Inc.
One Bush Street, 17th floor, San Francisco, CA 94104,
Attn: SF Prospectus Department
Before you invest, you should read the prospectus supplement and accompanying
prospectus, the registration statement, and the other documents that the
Company has filed with the Securities and Exchange Commission for more
complete information about the Company and this offering.
This press release does not and shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities, nor shall there be any
sale of the securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration of qualification
under the securities laws of any state or jurisdiction.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of human trials including a Phase III trial in head
and neck cancers using REOLYSIN^®, its proprietary formulation of the human
This press release contains forward-looking statements within the meaning of
the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act
of 1934, as amended, and forward-looking information within the meaning of
Canadian securities laws. Statements, other than statements of historical
facts, included in this press release that address activities, events or
developments that Oncolytics expects or anticipates will or may occur in the
future, including such things as the intended use of proceeds and other such
matters are forward-looking statements and forward-looking information and
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements and forward-looking information. Such risks and
uncertainties include, among others, risks related to the Company's business
which may result in the intended use of proceeds changing. Investors should
consult the Company's quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and uncertainties
relating to the forward-looking statement and forward-looking information.
Investors are cautioned against placing undue reliance on forward-looking
statements and forward-looking information. The Company does not undertake to
update these forward-looking statements and forward-looking information,
except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
210, 1167 Kensington Cr NW
Calgary, Alberta T2N 1X7
The Equicom Group
300 5^th Ave. SW, 10^th Floor
Calgary, Alberta T2P 3C4
Dian Griesel, Inc.
396 West Broadway, 2^nd Floor
New York, NY 10012
Press spacebar to pause and continue. Press esc to stop.